Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eledon Pharmaceuticals (ELDN)
NASDAQ:ELDN
Eledon Pharmaceuticals (ELDN) Stock Price & Analysis
622 Followers
ELDN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.07 - $2.95
Previous Close$1.86
Volume313.63K
Average Volume (3M)84.61K
Market Cap
$48.88M
Enterprise Value-$14.12M
Total Cash (Recent Filing)$59.61M
Total Debt (Recent Filing)$479.00K
Price to Earnings (P/E)-1.0
Beta0.19
Next Earnings
May 09, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding24,813,130
10 Day Avg. Volume111,142
30 Day Avg. Volume84,610
Standard Deviation0.32
R-Squared0.02
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.51
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.18
Forecast
1Y Price Target
$15.60Price Target Upside672.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Eledon Pharmaceuticals News
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analysts
PremiumPre-Earnings
Is ELDN a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementELDN reaffirmed timelines across their clinical program for lead asset tegoprubart in kidney transplantation, showing commitment to progress and consistency in development.
Innovative ApplicationTegoprubart's use in the first-ever transplant of a kidney from a genetically modified pig to a human highlights its innovative application and potential as a best-in-class therapeutic.
Positive Clinical DataPreliminary data from 11 subjects continue to be encouraging and suggest that tegoprubart is effective in the prevention of kidney transplant rejection while being generally safe and well-tolerated.
Bears Say
Clinical Trial RisksThere's a risk of stock devaluation if the company's clinical trials fail to meet their objectives.
Financial StabilityThe company may face financial instability as it only has 1.1 years of cash left to fund operations.
Regulatory And Commercial ChallengesInvestors could be concerned about potential additional regulatory requirements and the company's unproven strategy for commercializing its products.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ELDN FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was $1.07 and its highest was $2.95 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Currently, no data Available
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is May 09, 2024 which is in 16 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on Mar 28, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.358 by $0.038.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -$0.37.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 24,198,130 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.358. Following the earnings report the stock price went down -3.398%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Among the largest hedge funds holding Eledon Pharmaceuticals’s share is Woodline Partners LP. It holds Eledon Pharmaceuticals’s shares valued at 1M.
---
Eledon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.60 (672.28% Upside)
$15.60 (672.28% Upside)
Hedge Fund Trend
Increased
By 85.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 47.7%
Last 30 Days ▲ 73.6%
Last 30 Days ▲ 73.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.77%
12-Months-Change
Fundamentals
Return on Equity
-48.12%
Trailing 12-Months
Asset Growth
35.67%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. (Nasdaq:ELDN) is an immunology-focused biotechnology company utilizing its experience in the CD40/CD40L costimulatory pathway to develop and commercialize precision therapies for persons undergoing organ and cellular transplantation, and for people living with autoimmune and neurodegenerative disease. The company’s lead compound in development is tegoprubart (AT-1501), an anti-CD40L antibody. The company, which was established in 2004, is headquartered in Irvine, CA.
---
ELDN Earnings Call
Q1 2023
0:00 / 0:00
---
ELDN Stock 12 Months Forecast
Average Price Target
$15.60
▲(672.28% Upside)
Technical Analysis
Best Analysts Covering ELDN
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-2.54%
reiterated a buy rating last month
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -2.54% per trade.
---